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Introduction
Nucleic acids like DNA and mRNA have been used to develop 
vaccines for priming of tumor-specific cytotoxic T lymphocytes 
(CTLs). Compared with other antigen forms like proteins, 
nucleic acids are easy to produce and can be engineered to 
target antigen-derived epitopes to both the major histocom-
patibility complex I (MHC I) and MHC II antigen-presenting 
pathways. As such nucleic acid vaccines enable activation 
of strong antitumor T-cell responses.1,2 In contrast to DNA, 
the use of mRNA does not require nuclear translocation or 
transcription to mediate protein expression. Moreover, the 
use of mRNA is not faced with the risk of genomic integra-
tion of the delivered sequence. Consequently, tumor antigen 
encoding mRNA has been studied as an off-the-shelf cancer 
vaccine.2–4 The use of mRNA for cancer vaccination brings 
forth the challenge of its delivery to antigen-presenting cells 
(APCs). In this regard, the existence of multiple APC types, 
their different location, the mode of mRNA uptake, and finally 
their activation by mRNA should be considered.
APCs are a heterogeneous group of cells that have the 
ability to capture, process, and present antigens to T cells. 
Dendritic cells (DCs) are considered professional APCs, as 
they can initiate primary T-cell responses. Therefore, several 
strategies have been devised to target DCs.5–8 However, a 
recent study underscored that selective targeting of anti-
gens to DCs does not result in strong antigen-specific T-cell 
responses. Strong T-cell stimulation was only observed when 
the antigen was also targeted to macrophages, another 
important APC subset.7 These data suggest that mRNA vac-
cines should be delivered to both DCs and macrophages to 
function optimally.
Furthermore, it was shown that the location of mRNA deliv-
ery determines the strength of the ensuing immune response. 
Antigen mRNA formulated in lactated Ringer’s solution has 
been delivered to CD11c+ cells within lymph node and skin. 
Intranodal delivery of mRNA resulted in stronger immune 
responses than its delivery in skin, most likely because intra-
nodal DCs are intimately associated with T cells.9,10 However, 
intranodal delivery of vaccines in mice is invasive, requiring 
an incision to expose the lymph node. In humans, intrano-
dal delivery of mRNA is performed under ultrasound guid-
ance and although well tolerated, it is challenging. Therefore, 
alternative routes of delivering mRNA like intrasplenic and 
i.v. injection have been evaluated.11–13 These approaches 
envisage mRNA transfection of splenic APCs that are also 
intimately associated with T cells and were shown to effi-
ciently activate antigen-specific CTLs. Importantly, intras-
plenic and i.v. delivery of mRNA requires its encapsulation 
to protect the mRNA from degradation by ribonucleases.14,15 
Nonviral mRNA encapsulation is often performed using lip-
ids, polymers, and combinations thereof.2 The resulting 
nanoparticles and (sometimes) microparticles have been 
tested in vivo with varying success using i.v., s.c, i.d., i.p., 
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Cancer vaccines based on mRNA are extensively studied. The fragile nature of mRNA has instigated research into carriers 
that can protect it from ribonucleases and as such enable its systemic use. However, carrier-mediated delivery of mRNA has 
been linked to production of type I interferon (IFN) that was reported to compromise the effectiveness of mRNA vaccines. In 
this study, we evaluated a cationic lipid for encapsulation of mRNA. The nanometer-sized, negatively charged lipid mRNA 
particles (LMPs) efficiently transfected dendritic cells and macrophages in vitro. Furthermore, i.v. delivery of LMPs resulted 
in rapid expression of the mRNA-encoded protein in spleen and liver, predominantly in CD11c+ cells and to a minor extent in 
CD11b+ cells. Intravenous immunization of mice with LMPs containing ovalbumin, human papilloma virus E7, and tyrosinase-
related protein-2 mRNA, either combined or separately, elicited strong antigen-specific T-cell responses. We further showed 
the production of type I IFNs upon i.v. LMP delivery. Although this decreased the expression of the mRNA-encoded protein, it 
supported the induction of antigen-specific T-cell responses. These data question the current notion that type I IFNs hamper 
particle-mediated mRNA vaccines.
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i.m., and recently i.n. injections.16,17 An issue that arose dur-
ing this preclinical work is the immunogenicity of particulate 
mRNA. Its delivery to APCs has been linked with the induc-
tion of strong type I interferon (IFN) responses.18–23 This 
innate immune response is elicited through the interaction 
of the mRNA with pattern-recognition receptors like toll-like 
receptors (TLRs) and retinoic acid-inducible protein I.18,21,24 In 
the context of mRNA vaccines, it was suggested that type I 
IFNs compromise transgene expression and as such induc-
tion of antigen-specific immunity.19,20 These data imply that 
an ideal anticancer mRNA vaccine should enable systemic 
delivery of tumor antigen mRNA to DCs and macrophages 
with minimal induction of type I IFNs in order to initiate strong 
CTL responses. We evaluated the encapsulation of mRNA in 
Lipofectamine RNAiMAX, a proprietary lipid formulation, as 
lipids are biocompatible and biodegradable. Moreover, lipid 
particles are highly versatile as their characteristics can be 
altered for instance through PEGylation or inclusion of tar-
geting moieties. We addressed the best suited mRNA:lipid 
ratio for packaging and subsequent in vitro transfection of 
DCs and macrophages. We further examined the kinetics 
and location of the expression of the mRNA-encoded antigen 
after systemic delivery of lipid mRNA particles (LMPs) and 
whether APCs were transfected in vivo. Induction of antigen-
specific CTLs was evaluated, addressing whether multiple 
antigens could be delivered simultaneously without affecting 
the strength of the CTL response. Finally, we examined the 
induction of type I IFNs and how these impacted on the anti-
gen expression and CTL response.
Results
Efficient in vitro transfection of DCs and macrophages 
with LMPs
To establish whether Lipofectamine RNAiMAX, a cationic 
lipid, can package and protect mRNA, we admixed mRNA 
encoding truncated nerve growth factor receptor or Firefly 
luciferase (Fluc) at different mass (RNA in µg) per volume 
(lipid in µl) ratios with this lipid. The electrophoretic mobility 
shift assay showed that mRNA was completely packaged in 
LMPs at an mRNA:lipid ratio of 1:6, as the mRNA did not 
migrate in the agarose gel, whereas at a 1:2 and 1:4 ratio, 
free mRNA was detectable (Figure 1a). This free mRNA rep-
resented 50% and 25% of the total mRNA (data not shown), 
respectively, and was degraded upon exposure to serum 
(Figure 1b). The LMPs obtained through mRNA packaging 
at an mRNA:lipid ratio of 1:6, exhibited >5 µm diameter with a 
high polydispersity index and a negative surface charge, indi-
cating the formation of large aggregates when all the mRNA 
is complexed with the lipid. At an mRNA:lipid ratio of 1:2 and 
1:4, nanometer-sized particles with a lower polydispersity 
index were formed. Due to the relative excess of mRNA over 
lipid, these LMPs exhibited a more negative surface charge 
(Table 1). Flow cytometry measurements showed efficient 
in vitro transfection of human embryonal kidney (HEK) 293T 
cells in OptiMem with LMPs containing mRNA encoding 
enhanced green fluorescent protein (eGFP). Importantly, 
both the cell viability and transfection efficiency decreased 
when more lipids were used to package the same amount 
of mRNA (Figure 1c–e). Therefore, subsequent experiments 
were performed with LMPs generated at a 1:2 mRNA:lipid 
ratio. As the LMPs were intended for i.v. immunization, we 
also assessed the transfection efficiency of bone marrow-
derived DCs and RAW246.7 macrophages. The results on 
CD11c+ DCs and CD11b+ macrophages showed high trans-
fection efficiency in OptiMem as well as serum-containing 
medium (Figure 1f,g). Importantly, in the presence of serum, 
the level of protein expression was significantly higher com-
pared with the situation in serum-free medium (Figure 1f,g), 
underpinning the suitability of the presented particles for the 
intended in vivo applications.
Intravenous but not s.c. or i.m. delivery of LMPs results 
in potent antigen-specific T-cell responses
To address whether LMPs are promising as a vaccine can-
didate, we first evaluated the expression of Fluc after i.v., 
s.c., and i.m. delivery of LMPs containing 10 µg Fluc mRNA. 
Expression of the Fluc protein was evaluated 24 hours later 
using in vivo bioluminescence imaging. Expression of Fluc 
was detectable after i.v. and i.m. delivery of the LMPs, while 
it was not detectable after their s.c. delivery (Figure 2a,b). 
Next, we evaluated the stimulation of ovalbumin (OVA)-
specific T cells after i.v., s.c., and i.m. delivery of LMPs con-
taining 5 µg OVA mRNA. The expansion of OVA-specific 
CD8+ T cells was evaluated in flow cytometry using MHC 
Dextramers for detection of H-2Kb/SIINFEKL (OVA)-specific 
T cells, while their cytolytic activity was evaluated using an 
in vivo cytotoxicity assay. Intravenous delivery of OVA mRNA 
containing LMPs resulted in the strongest expansion of OVA-
specific CD8+ T cells (Figure 2c). In accordance with this 
result, we observed the strongest lyses of OVA-presenting 
target cells after i.v. delivery of the LMPs (Figure 2d). Based 
on these results, we continued with i.v. delivery of LMPs in 
the following experiments.
Intravenous delivery of LMPs results in protein 
expression in spleen and liver
To evaluate the in vivo mRNA transfection kinetics after sys-
temic delivery of LMPs, we packaged 10 µg Fluc mRNA and 
injected it intravenously in C57BL/6 mice. Expression of the 
Fluc protein was evaluated using in vivo bioluminescence 
imaging. We showed Fluc expression as soon as 15  minutes 
after injection and could detect Fluc expression up to 4 days 
after injection (Figure 3a,b). To determine which organs 
exhibited Fluc expression, we isolated lymph nodes, spleen, 
liver, lung, intestines, heart, kidneys, and stomach 4 hours 
after LMP delivery, showing positivity in the spleen and liver 
(Figure 3c).
Protein expression after i.v. delivery of LMPs is detected 
in CD11c+ and CD11b+ cells
Next, we addressed whether APCs, in particular CD11c+ 
DCs, express the mRNA-encoded protein upon i.v. delivery 
of LMPs, since this is critical for the subsequent activation 
of antigen-specific immunity. Therefore, we delivered Fluc 
LMPs (10 µg mRNA) intravenously in wild-type C57BL/6 and 
CD11c diphtheria toxin receptor transgenic mice. The latter 
were pretreated with diphtheria toxin, resulting in a depletion 
of CD11c+ cells. Expression of Fluc protein was assessed 
4 hours after LMP delivery using in vivo bioluminescence 
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imaging. Although we observed a significant decrease in 
luminescent signal in mice depleted for CD11c+ cells, we 
could still detect the expression of Fluc protein in the liver 
and spleen (Figure 4a,b). This indicates that CD11c+ cells 
are mainly, but not exclusively, responsible for the uptake and 
translation of mRNA delivered as LMPs. To confirm these 
findings and evaluate whether CD11b+ cells are corespon-
sible for the mRNA uptake, we next delivered LMPs contain-
ing Thy1.1 mRNA intravenously to Thy1.2 C57BL/6 mice. To 
ensure a detectable percentage of Thy1.1+ (mRNA trans-
fected) cells, we delivered 20 µg mRNA. Four hours later, 
we performed flow cytometry measurements on spleen cells, 
showing that only a small fraction of spleen cells were Thy1.1+ 
(Figure 4c). These Thy1.1+ cells mainly consisted of CD11c+ 
cells, whereas a minor fraction was CD11b+ (Figure 4d).
Figure 1  Efficient in vitro transfection of dendritic cells (DCs) and macrophages with lipid mRNA particles (LMPs). (a,b) Electric 
mobility shift assay of mRNA packaged at different mRNA:lipid ratios. mRNA formulated in 0.8 lactated Ringer’s solution served as a control. 
In a the samples were not exposed to serum, whereas in b the samples were incubated with 10% fetal clone I serum for 30 minutes. The 
photographs show representative pictures of the three independent experiments. Lanes 1 to 5 represent: (1) ladder; (2) mRNA in 0.8 lactated 
Ringer’s solution; LMPs at a 1:2 (ref. 25); (4) 1:4, and (5) 1:6 ratio. (c) Representative histogram of 5 × 105 human embryonal kidney 293T cells 
transfected with 2.5 µg enhanced green fluorescent protein (eGFP) mRNA packaged at different mRNA:lipid ratios. Transfection was performed 
in OptiMem. Twenty-four hours later, cells were harvested, counted by trypan blue staining to determine the percentage of live/dead cells, 
and evaluated in flow cytometry for the expression of eGFP. The graph in d depicts the percentage of eGFP+ cells after transfection (n = 5). 
The graph in e depicts the cell viability after transfection (n = 5). (f) Five hundred thousand DCs were transfected with 2.5 µg eGFP mRNA, 
complexed at a 1:2 mRNA:lipid ratio in the absence or presence of serum. The graph depicts the percentage and the mean fluorescence 
intensity (MFI) of eGFP+ cells (n = 3). (g) Five hundred thousand RAW246.7 macrophages were transfected with 2.5 µg eGFP mRNA 
complexed at a 1:2 mRNA:lipid ratio in the absence or presence of serum. Twenty-four hours later, cells were harvested and evaluated in flow 
cytometry for the expression of eGFP. The graph depicts the percentage and the MFI of eGFP+ cells (n = 4). The graphs in d–g summarize 
the results of the indicated number of experiments as mean ± SEM. ns, not significant.
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Table 1 Characterization of LMPs
Ratio 
mRNA:lipid Diameter (nm) PDI Zeta potential (mV)
0:1 1,999 ± 462 0.794 ± 0.163 +29.0 ± 4.48
1:2 242.3 ± 32.6 0.310 ± 0.051 −58.9 ± 4.6
1:4 316.9 ± 54.0 0.327 ± 0.033 −53.4 ± 2.6
1:6 5,404 ± 1,588 0.424 ± 0.120 −32.4 ± 6.7
Hydrodynamic diameter, PDI, and zeta potential results for s generated 
at different mRNA:lipid ratios. Data are noted as mean ± SD (n = 6). 
PDI, polydispersity index; LMPs, lipid mRNA particles.
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Intravenous delivery of LMPs induces antigen-specific 
CTLs
To further study whether i.v. delivery of LMPs induces effec-
tor cells that can specifically lyse target, we performed an 
in vivo cytotoxicity assay. We delivered LMPs formulated at 
an mRNA:lipid ratio of 1:2 that contained different amounts of 
mRNA encoding OVA. We showed that as little as 1 µg of OVA 
mRNA was sufficient to induce strong lyses of OVA-present-
ing target cells (>60%; Figure 5a). Dose-dependent induc-
tion of CTLs specific for the human papilloma virus (HPV) 
E7 antigen was also observed (Figure 5b).  Importantly, CTL 
responses against HPV E7 could be significantly enhanced 
when LMPs (1 µg HPV E7 mRNA) were delivered 3 times at 
a 5-day interval (Figure 5c).
It has been shown that the differential MHC affinity of 
peptides results in the so-called CTL immunodominance.26 
Therefore, APCs are often only loaded with one antigen to 
avoid competition between peptides for binding to MHC mol-
ecules and as such avoid skewing of the immune response. 
We further addressed whether delivery of multiple mRNA 
molecules encoding distinct antigens would result in simi-
lar target cell lysis as delivery of each antigen mRNA sepa-
rately. Therefore, we injected LMPs containing three different 
antigen mRNA molecules (5 µg/mRNA) encoding OVA, HPV 
E7, or tyrosinase-related protein-2 and compared the induc-
tion of CTLs to delivery of LMPs containing mRNA for one 
of the aforementioned antigens supplemented with mRNA 
encoding truncated nerve growth factor receptor (control) 
to ensure delivery of equal amounts of mRNA. We showed 
similar induction of OVA-, HPV E7-, and tyrosinase-related 
protein-2-specific CTLs in mice immunized with LMPs con-
taining only one type or multiple types of antigen mRNA mol-
ecules (Figure 5d–f).
Type I IFNs induced upon i.v. delivery of lipid:RNA 
particles support CTL activation
In order to evaluate the induction of a type I IFN response 
after systemic delivery of LMPs, we first determined the 
expression of Mx1 in splenocytes using quantitative real-
time polymerase chain reaction, as the transcription of 
this gene is upregulated upon stimulation with type I IFNs. 
Therefore, splenocytes were isolated from nontreated mice 
(control) and mice that were injected intravenously with 
LMPs (10 µg mRNA) 24 hours prior to splenectomy. We 
showed that i.v. delivery of LMPs resulted in increased levels 
of Mx1, indicating the production of type I IFN (Figure 6a). 
Figure 2 Intravenous but not s.c. or i.m. delivery of lipid mRNA particles (LMPs) results in potent ovalbumin (OVA)-specific T-cell 
responses. (a) Representative in vivo bioluminescence images after s.c., i.m., or i.v. delivery of 10 µg Fluc mRNA (n = 4). (b) The graph 
summarizes the results shown in a as mean ± SEM (n = 4). (c,d) C57BL/6 mice received a s.c., i.m., or i.v. injection with LMPs containing 5 µg 
OVA mRNA. Five days later, we performed c a major histocompatibility complex (MHC) Dextramer staining to detect H-2Kb/SIINFEKL (OVA)-
specific T cells and d an in vivo cytotoxicity assay to detect lyses of OVA-presenting target cells (n = 4). SC, subcutaneous; IM, intramuscular; 
IV, intravenous; ns, not significant.
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Figure 3 Kinetics of the in vivo expression of the mRNA-encoded protein after i.v. delivery of lipid mRNA particles (LMPs). 
(a) Representative in vivo bioluminescence images of the same mouse at different time points after i.v. injection of 10 µg Fluc mRNA packaged 
at a mRNA:lipid ratio of 1:2 (n = 4). (b) The graph depicts the expression of Fluc at the indicated time points, summarizing the results as mean 
± SEM (n = 4). (c) Representative bioluminescence image of organs that were excised 4 hours after i.v. delivery of 10 µg Fluc mRNA to confirm 
the Fluc expression in the spleen and liver (n = 7).
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Figure 4 Intravenous delivery of lipid mRNA particles (LMPs) results in protein expression in CD11c+ cells. (a) Representative in vivo 
bioluminescence images out of two individual experiments of CD11c-diphteria toxin receptor mice (CD11c−) or littermates (CD11c+) that were 
treated with dihphteria toxin 24 hours prior to i.v. injection of 10 µg Fluc mRNA packaged at a mRNA:lipid ratio of 1:2. Mice with an intact 
CD11c+ cell population that received an i.v. injection of 10 µg truncated nerve growth factor receptor (tNGFR) mRNA packaged at a mRNA:lipid 
ratio of 1:2 served as a negative control (n = 8–10). (b) The graph summarizes the results of the Fluc expression as shown in a as mean ± 
SEM (n = 8–10). (c) Representative flow cytometry plots showing the expression of Thy1.1 mRNA in splenic cells from a mouse injected with 
20 µg tNGFR mRNA (control) or Thy1.1 mRNA (n = 3). (d) Representative flow cytometry plot showing the percentage CD11c+ and CD11b+ 
cells in the Thy 1.1+ population after i.v. injection of Thy 1.1 mRNA (n = 3). 
ph
/s
/c
m
2 /s
r
200,000
**
150,000
100,000
50,000
0
CD11c− CD11c+
Control
250
200
150
100
50
0
−375
103 104 105 0
Thy1.1 CD11c
4.4%
65%
−333
103 104 105 0
−1.542
−
97
4
103 104 105
105
104
103
0
250
0.1%0.0%
200
150
100
50
FS
C
(× 
1,
00
0)
(× 
1,
00
0)
LMP LMP
CD
11
b
c d
b
ph/s/cm2/sr20 40 60 80
Control
×103
CD11c− CD11c+
a
Molecular Therapy—Nucleic Acids
Type I IFN and mRNA
Broos et al
6
The induction of type I IFNs was confirmed in enzyme-
linked immunosorbent assay on sera that were collected 2, 
6, and 24 hours after i.v. delivery of LMPs, showing a peak 
in IFN-α concentration at 6 hours (Figure 6b). We next com-
pared the expression of Fluc protein upon systemic delivery 
of Fluc LMPs (10 µg) in wild-type C57BL/6 and interferon-
alpha  receptor (IFNAR) knockout mice (IFNAR−/−) to assess 
whether the protein expression is reduced due to type I IFN 
production. We observed that expression of Fluc was signifi-
cantly enhanced in IFNAR−/− mice (Figure 6c). Finally, we 
determined whether the reduced expression of the mRNA-
encoded protein due to type I IFNs hampered the induction 
of CTLs. Therefore, an in vivo cytotoxicity assay was per-
formed in wild-type C57BL/6 and IFNAR−/− mice to measure 
the induction of OVA-specific CTLs. Surprisingly, we showed 
a reduction in specific lysis in IFNAR−/− mice, despite the 
aforementioned higher bioavailability of the mRNA-encoded 
protein (Figure 6d). These results suggest that induction of 
CTLs upon systemic delivery of LMPs is supported by type 
I IFN production rather than counteracted.
Figure 5 Delivery of lipid mRNA particles (LMPs) results in the induction of antigen-specific lysis. (a) C57BL/6 mice were injected 
intravenously with LMPs containing varying amounts of ovalbumin (OVA) mRNA (plus truncated nerve growth factor receptor (tNGFR) mRNA). 
Five days later, an in vivo cytotoxicity assay was performed (n = 6–13). (b) Mice were injected intravenously with 5 µg or 1 µg E7 mRNA (plus 
tNGFR mRNA; n = 4). (c) Comparison of a single versus three injections at a 5-day interval of 1 µg E7 mRNA (n = 4). The graphs in (a–c) depict 
the percentage specific lysis as mean ± SEM. (d–f) Intravenous injection of multiple (5 µg per antigen) versus one antigen mRNA molecule 
(5 µg antigen mRNA plus tNGFR mRNA). The graphs in d, e, and f depict the percentage specific lysis of target cells presenting OVA, human 
pappiloma virus E7, or tyrosinase-related protein-2 (Trp2), respectively (n = 3–5). ns, not significant.
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Figure 6: Type I interferon (IFN) induced by i.v. delivery of lipid mRNA particles (LMPs) enhances antigen-specific immune 
responses. (a) Mx1 quantitative real-time polymerace chain reaction on mRNA extracted from the spleen 6 hours after i.v. delivery of LMPs. 
The graph depicts the 2−ΔCt values as mean ± SEM (n = 4). (b) IFN-α ELISA of blood samples collected 2, 6 and 24 hours after i.v. injection 
of LMPs. The graph depicts the concentration of IFN-α (ng/ml) as mean ± SEM. (c) Wild type or IFNAR−/− mice received an i.v. injection of 10 
µg Fluc mRNA. Four hours later, we performed in vivo bioluminescence imaging. The graph depicts the Fluc expression as mean ± SEM 
(n = 8–10). (d) Wild type or IFNAR−/− mice received an i.v. injection with LMPs containing the 5 µg OVA mRNA. Five days later, we performed 
the in vivo cytotoxicity assays. The percentage-specific lysis is shown in the graph as mean ± SEM (n = 6–7).
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Discussion
In this report, we show that Lipofectamine RNAiMAX, a cat-
ionic lipid that has been extensively explored for delivery of 
small interfering RNA, can be used for systemic delivery of 
mRNA for cancer immunotherapy purposes.
Since the physicochemical characteristics of particles 
critically influence their uptake by phagocytic cells, we first 
evaluated the charge and size of LMPs generated at dif-
ferent mRNA:lipid ratios. We showed that nanometer-sized 
particles with a negative charge were obtained at a 1:2 and 
1:4 ratio, whereas micrometer-sized particles that also have 
a negative charge were obtained at a 1:6 ratio. The nega-
tive charge of the LMPs at a 1:2 and 1:4 ratio can in part 
be explained by the presence of noncomplexed mRNA as 
shown in the electrophoretic mobility shift assay. However, 
as the LMPs prepared at a 1:6 ratio also showed a nega-
tive charge without evidence of noncomplexed mRNA, the 
negative zeta potential of these LMPs can likely be attrib-
uted to a structural configuration where the majority of the 
mRNA is attached to the exterior of the particle, rather than 
encapsulated within the liposomes as previously reported 
for DNA-based lipoplexes. Overall, such a negative surface 
charge could be beneficial, as it has been described for DNA-
based lipoplexes that a negative charge enables uptake of 
nanoparticles via phagocytosis.27,28 Size is another key factor 
that determines the uptake efficiency of nanoparticles.29–31 It 
was shown that nanometer-sized particles are internalized by 
various cell types, including fibroblasts, macrophages, and 
DCs.32,33 Therefore, it is no surprise that delivery of mRNA to 
HEK293T cells was most efficacious when using LMPs gen-
erated at a 1:2 ratio (242.3 ± 32.6 nm; −58.9 ± 4.6 mV). Since 
we further observed that particles generated with increas-
ing amounts of Lipofectamine RNAiMAX negatively affected 
the cell viability, we proceeded with LMPs prepared at a 1:2 
mRNA:lipid ratio to evaluate transfection of APCs.
In vitro transfection of bone marrow-derived DCs and 
RAW246.7 macrophages was performed in the absence as 
well as presence of serum. In this way, we indirectly evaluated 
the uptake of noncomplexed mRNA, which is still observed at 
a 1:2 LMP formulation and moreover gained information on 
the potential of the mRNA–lipoplexes for systemic delivery. 
It is generally accepted that the presence of serum can lead 
to particle aggregation,34–37 resulting in changes in physico-
chemical characteristics and as such different particle uptake 
and sometimes even premature release of its content.38 
However, we observed the opposite, a higher percentage 
of DCs and macrophages expressed the mRNA-encoded 
protein and at higher levels when LMPs were delivered in 
serum-containing cultures. These observations exclude that 
noncomplexed mRNA is engulfed as we showed in the elec-
tric mobility shift assay that free mRNA is degraded upon 
contact with serum. Moreover, these data suggest that the 
studied nanoparticles are suited for the intended systemic 
delivery of mRNA. Also Marchini et al.39 observed enhanced 
transfection efficiency of murine fibroblasts using lipid:DNA 
complexes in the presence of serum. This was linked to an 
increase in particle stability and particle size,39 which in turn 
has been linked to enhanced uptake and trafficking to the 
cytosol.40 As the relation between the structural properties 
of mRNA–lipoplexes has not yet been as extensively studies 
as for their DNA-based counterparts, one could consider a 
plethora of factors that might explain the difference in trans-
fection efficiency in serum-free versus serum-containing 
media. In addition to the particle’s size and surface charge, 
one such factor could be the adsorption of serum proteins to 
the surface of LMPs. It has been described that adsorption 
of proteins like alpha-2-human serum glycoprotein and the 
opsonin immunoglobulin G to different microparticles pro-
motes phagocytosis by immune cells.41 Another factor is the 
behavior of phagocytic cells in the presence of serum. It is 
known that serum in medium has marked effects on several 
properties of DCs, including their transfectability.42 Moreover, 
it has been described that the phagocytic capacity of mono-
nuclear cells increases when cultured in increasing amounts 
of fetal bovine serum.42–44
Since LMPs generated at a mRNA:lipid ratio of 1:2 effi-
ciently transfected APCs in vitro, we evaluated them in vivo. 
Using in vivo bioluminescence imaging and LMPs contain-
ing Fluc mRNA, we evaluated the timing and location of 
Fluc expression. We observed Fluc in the spleen as soon as 
15 minutes after systemic injection of LMPs. The signal in 
the spleen accumulated over a period of 4 hours and after-
ward decreased over a period of 4 days. We furthermore 
observed expression of Fluc in the liver 4 hours after i.v. 
LMP delivery. It has been described that interaction of cat-
ionic particles and serum proteins after in vivo delivery can 
cause aggregation. The observed mRNA delivery to cells in 
liver and spleen using the LMPs prepared with Lipofectamine 
RNAiMAX argues against the formation of large aggregates 
in vivo. However, it cannot be entirely excluded that a fraction 
of the LMPs does not reach target organs. Therefore, it would 
be of interest in future studies to follow the distribution of the 
LMPs for instance using fluorescence or radioactive labeling 
and evaluate whether the location of the LMPs completely 
overlaps with the location of protein expression.
It has been described that after i.v. delivery, lipid-based 
nanoparticles first enter the spleens’ marginal zone that con-
tains DCs and macrophages, which in turn are character-
ized by their ability to engulf particulates.43 Therefore, it is 
not surprising that we detected the expression of the mRNA-
encoded protein in CD11c+ and CD11b+ cells after i.v. deliv-
ery of LMPs. Importantly, flow cytometry showed that mainly 
CD11c+ cells are responsible for the mRNA uptake. Nonethe-
less, the study by Ciavarra et al.44 on the role of splenic DCs 
and macrophages in generating antiviral immunity suggests 
that CD11b+ cells should not be disregarded when it comes 
to their contribution to induce antigen-specific immunity.
We could show that i.v. administration of LMPs contain-
ing antigen mRNA results in strong antigen-specific immune 
responses. Importantly, these responses could be induced 
with as little as 1 µg antigen mRNA and could be signifi-
cantly enhanced through repeated vaccination. Moreover, we 
addressed whether i.v. delivery of LMPs containing a mixture 
of mRNA molecules encoding three different antigens would 
evoke antigen-specific responses that are equally potent as 
the antigen-specific immune response elicited upon delivery 
of LMPs containing only one antigen mRNA. The latter was 
performed as most often DCs for cancer vaccination pur-
poses are loaded with only one antigen to avoid competition 
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between antigen-derived peptides for binding to MHC mol-
ecules and as such avoid a bias of the immune response. 
However, the ability to package and deliver multiple antigen 
mRNA molecules in one LMP would make the product com-
mercially more attractive, since it takes the heterogeneity of 
tumors into account. Similar to the observations made by 
Schaft et al.,45 who electroporated human DCs with mRNA 
encoding three different antigens, we did not observe a nega-
tive influence on the presentation of the antigen and in our 
setting the subsequent in vivo elimination of antigen-present-
ing target cells.
Finally, we evaluated whether i.v. delivery of LMPs results 
in the induction of type I IFNs and is so, how these impact on 
vaccine efficacy. The latter is important as data from Pollard 
et al.20 suggest that type I IFN in the context of mRNA vacci-
nation is detrimental for the ensuing immune response. None-
theless, in several non-mRNA studies, type I IFN has been 
linked to protective CD8+ T-cell responses.46–48 Moreover, we 
previously performed a study in which mRNA encoding a 
fusokine consisting of IFN-β fused to the ectodomain of the 
transforming growth factor -beta receptor II (TGF-βIIR) was 
used to stimulate antitumor immunity.49 These studies ques-
tion the notion that type I IFN hampers the efficacy of mRNA-
based vaccines and warrant further investigation into this 
topic. Since we observed transient production of type I IFN 
after i.v. delivery of LMPs, we evaluated whether this lowered 
the expression of the mRNA-encoded protein as described 
by several other groups.18,19,22,23 Using IFNAR−/− mice and 
i.v. delivery of Fluc mRNA, we showed that the type I IFN 
response indeed negatively affected Fluc expression. It was 
previously shown that the bioavailability of the antigen is a key 
factor that determines the induction of antigen-specific CTLs 
after mRNA vaccination.9,50 Therefore, we were surprised that 
despite higher protein expression, the lysis of target cells in 
LMP-vaccinated IFNAR−/− mice was significantly lower when 
compared with the target cell lysis in LMP-vaccinated wild-
type mice. Interestingly, DCs generated from bone marrow 
from IFNAR−/− mice are less mature.20 This might in part 
explain our results since immature DCs have a higher phago-
cytic capacity and as such ability to engulf (at least) naked 
mRNA.50 However, immature DCs possess a lower capacity 
to activate CTLs.51 Alternatively, the lower vaccine efficacy 
despite higher protein expression in IFNAR−/− mice could be 
explained in light of several studies, which show that presen-
tation of low amounts of antigens results in the stimulation of 
T cells with a high avidity T-cell receptor. These T cells have 
a better functionality.25,52,53 One could argue that CD8+ T cells, 
activated in wild-type mice might have a higher avidity T-cell 
receptor, an issue that should be addressed experimentally.
Clearly, more research needs to be performed to study the 
role of type I IFNs in the induction of immunity by particu-
late mRNA-based cancer vaccines, as subtle differences in 
DC activation and T-cell receptor avidity are unlikely to fully 
explain the difference in vaccination outcome in wild type ver-
sus IFNAR−/− mice. In this regard, a lot can be learned from 
studies on infection with viruses carrying a single-stranded 
RNA genome. Both mRNA in particulate form54–56 and RNA 
viruses57–59 trigger pattern-recognition receptors, like TLR3 
and TLR7. From studies with RNA viruses, we learned 
that type I IFNs have direct and indirect effects on multiple 
immune cells. The direct effects involve their ability to acti-
vate APCs and to promote among others the production of 
IFN-γ by and survival of CD8+ T cells.49,60–62 Its indirect effects 
are often mediated through the induction of chemokines 
and cytokines to recruit and regulate the activity of various 
immune cells.63,64 Moreover, we learned that type I IFN pro-
duction can be attributed to various cell types like stromal 
cells, macrophages, and DCs, showing that there are dispa-
rate type I IFN sources.59 The impact of different type I IFN 
sources, as well as the impact of its timing and amount, was 
studied using lymphocytic choriomeningitis virus, a noncyto-
pathic RNA virus as a model.65 In this study, it was suggested 
that prolonged production of type I IFNs upon infection of 
macrophages is required alongside its transient production 
by DCs to induce strong anti-lymphocytic choriomeningitis 
virus CTLs. However, we showed that even the transient pres-
ence of type I IFN has a significant impact on the activation of 
CTLs. The latter might be explained by the fact that besides 
the timing, also the amount can determine the outcome of 
type I IFN stimulation. In this regard, it was shown that low 
concentrations of type I IFNs induce production of stimulatory 
cytokines, whereas higher levels of type I IFNs can dampen 
their production.66,67 Consequently, in vaccine-mediated 
immunity, the amount of type I IFN and its presence at the 
appropriate time and anatomic location might be critical.
In conclusion, we showed that Lipofectamine RNAiMAX 
is able to package and protect mRNA from degradation. We 
showed that LMPs can be delivered intravenously to various 
APCs and that simultaneous or separate delivery of even small 
amounts of antigen mRNA results in strong antigen-specific 
CTL responses. These are supported by type I IFNs that are 
transiently produced upon LMP delivery. Therefore, this study 
highlights the need to study methods for mRNA encapsulation 
in detail, in order to provide future groundwork in developing 
mRNA-based therapeutics that promote antitumor immunity.
Materials and methods
Mice and cell cultures. Female, 6 to 12 weeks old, C57BL/6 
mice were purchased from Charles River (Lyon, France). 
CD11c-diphteria toxin receptor mice in which CD11c+ cells are 
depleted upon treatment with 16 ng diphteria toxin/g mouse 
body weight (Sigma-Aldrich, Ghent, Belgium) were kindly pro-
vided by B. Lambrecht (University of Ghent, Ghent, Belgium). 
Mice lacking the type I IFN receptor (IFNAR−/−) were obtained 
from C. Libert (University of Ghent, Belgium). All animals were 
treated according to the European guidelines for animal exper-
imentation. Experiments were approved by the Ethical Com-
mittee for the use of laboratory animals of the Vrije Universiteit 
Brussel (Jette, Belgium). HEK 293T cells and RAW246.7 cells 
were cultured as recommended by the American Type Cul-
ture Collection. Single-cell suspensions were prepared from 
spleens and lymph nodes as described.9 Primary mouse bone 
marrow-derived DCs were generated from C57BL/6 mice as 
described.9
Packaging of mRNA. The vectors pGEM-Ii80tOVA, -truncated 
nerve growth factor receptor, and -deltaUTsig-tyrosinase-
related protein-2-DCL were described.9 A codon-optimized 
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version of the Mus musculus Thy1.1, the Fluc, the HPV E7, 
and the eGFP gene were purchased from GeneArt (Life Tech-
nologies, Ghent, Belgium) and cloned as a NcoI-XhoI frag-
ment in the vector pEtheRNA. All enzymes were purchased 
from Fermentas (Thermo Scientific, Brussels, Belgium). Prior 
to in vitro transcription, pGEM and pEtheRNA vectors were 
linearized with SpeI and BfuAI, respectively. In vitro transcrip-
tion was performed as described.9 One microgram of mRNA 
was packaged in 2 µl of Lipofectamine RNAiMAX (Life Tech-
nologies). Packaging was performed according to manufac-
turer’s instructions.
Electrophoretic mobility shift assay, size, and zeta potential 
measurement. One microgram Fluc mRNA was mixed with 2 
µl Lipofectamine RNAiMAX (Life Technologies) in a volume of 
10 µl OptiMem (Life Technologies). After 20 minutes of incu-
bation, 50% fetal clone I serum (HyClone, Erembodegem, 
Belgium) was added. mRNA formulated in 0.8 lactated Ring-
ers’ solution served as a control. Complexation of the mRNA 
in RNAiMAX and its degradation upon serum exposure were 
analyzed by gel electrophoresis on a 2.4% agarose gel that 
was run for 1 hour at 7 V/cm in the presence of ethidium bro-
mide. The size and charge of 3 µg of eGFP mRNA packaged 
in Lipofectamine RNAiMAX at different mRNA:lipid ratios in 
a total volume of 100 µl OptiMem and diluted to 1 ml with 
HEPES buffer were assessed using the Malvern Zetasizer 
3000HS (Worcestershire, UK).
In vitro transfection with packaged mRNA. Five hundred 
thousand HEK293T cells or RAW246.7 cells were trans-
fected with 2.5 µg eGFP mRNA complexed with 5 µl of Lipo-
fectamine RNAiMAX diluted in OptiMem to obtain a total 
volume of 100 µl. Cells were plated 24 hours before transfec-
tion in a six-well plate. Before transfection, cells were washed 
with OptiMem. The transfection mix was added to the cells 
and cells were incubated for 1 hour at 37°C, 5% carbon diox-
ide. Thereafter, cells were diluted in 2 ml of the appropriate 
medium. RAW246.7 cells were also transfected in the pres-
ence of serum. Therefore, LMPs were added directly to cell 
culture medium containing 5% fetal clone I serum. Transfec-
tion of bone marrow-derived DCs was performed at day 6 
of culture in a 24-well plate. The cell culture medium was 
removed and the LMPs containing 1 µg eGFP mRNA were 
added to 5 × 105 cells. After 2 hours incubation, the cells were 
recultured for 24 hours in the appropriate cell culture medium. 
To perform transfection in the presence of serum, LMPs were 
added directly into the cell culture medium containing 5% fetal 
clone I serum. Transfection efficiency was evaluated as eGFP 
expression 24 hours after transfection using flow cytometry.
Intravenous, s.c., and i.m. administration of mRNA C57BL/6 
mice, CD11c-diphtheria toxin receptor mice or IFNAR−/− mice 
were injected intravenously (250 µl), subcutaneously (250 µl), 
or intramuscularly (25 µl) with the indicated amount of LMPs.
In vivo bioluminescence imaging. In vivo bioluminescence 
imaging was performed as previously described.68
Flow cytometry. To characterize cells that were transfected 
in situ with Thy1.1 mRNA after i.v. injection of Thy1.1 LMPs, 
spleen was isolated, single-cell suspension prepared, and 
cells stained with a phycoerythrin-conjugated anti-Thy1.1 
antibody (clone OX7) combined with fluorescein isothiocy-
nate-conjugated antibodies against CD11b (clone M1/70) and 
AlexaFluor 647 (AF647)-conjugated antibodies against CD11c 
(clone N418) (Becton Dickinson, Erembodegem Belgium). To 
evaluate the efficiency of transfection of HEK293T cells with 
eGFP LMPs, the percentage of eGFP-positive cells was eval-
uated. To evaluate the efficiency of transfection of DCs and 
RAW246.7 cells with eGFP LMPs, DCs and RAW246.7 cells 
were stained with an allophycocyanin-conjugated anti-CD11c 
and a Peridinin-chlorophyll proteins-Cyanine 5.5 (PerCP-
Cy5.5) anti-CD11b antibody respectively. The expression 
of CD11c or CD11b and eGFP were measured using flow 
cytometry. Untreated cells served as a negative control. MHC 
Dextramers were used for the detection of H-2Kb/SIINFEKL-
specific T cells. The staining was performed according to the 
manufacturer’s instructions (Immudex, Copenhagen, Den-
mark). Data were collected using a FACSCanto flow cytome-
ter (Becton Dickinson) and analyzed using FACSDiva (Becton 
Dickinson) or FlowJo (Treestar, Ashland, Oregon) software.
In vivo CTL assay. Splenocytes from naive syngeneic mice 
were pulsed or not with 5 µM of the appropriate peptide for 
1 hour. Peptide-pulsed cells were labeled with 2.5 µM car-
boxyfluorescein succinimidyl ester after which they were 
mixed at a 1:1 ratio with 0.25 µM carboxyfluorescein suc-
cinimidyl ester-labeled nonpulsed cells. At least 107 cells 
were injected intravenously. Spleen and lymph nodes were 
analyzed 18 hours later by flow cytometry. The percentage-
specific lyses were calculated as described.9 The following 
peptides were purchased from Eurogentec (Liège, Belgium) 
and used: SIINFEKL (OVA), SVYDFFVWL (tyrosinase-
related protein-2), and H2NRAHYNIVTFCOOH (HPV E7).
Quantitative real-time polymerase chain reaction. Isola-
tion of total RNA from the spleen, its reverse transcription, 
and the quantitative real-time polymerase chain reaction 
analysis performed to evaluate the upregulation of the type 
I IFN-responsive gene Mx1 were performed as previously 
described.49
Enzyme-linked immunosorbent assay. The enzyme-linked 
immunosorbent assay to measure IFN-α was performed 
according to the manufacturer’s protocol (PBL Assay  Science 
Orléans, France).
Statistical analysis. The unpaired Student’s t-test was per-
formed to compare the data sets. Sample sizes are indicated 
in the figure legends. Number of asterisks in the figures indi-
cates the level of statistical significance: *P < 0.05, **P < 0.01, 
and ***P < 0.001. The results are shown in column graph as 
mean ± SEM.
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